(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 September 2013 (19.09.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/138586 A1

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2013/031314

(22) International Filing Date:
14 March 2013 (14.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/611,332 15 March 2012 (15.03.2012) US

(71) Applicant: **JANSSEN BIOTECH, INC.** [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US).

(72) Inventors: **CHEN, John**; 3210 Merryfield Row, San Diego, California 92121 (US). **FRANSSON, Johan**; 3210 Merryfield Row, San Diego, California 92121 (US). **FURSOV, Natalie**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **HAMEL, Damon**; 3210 Merryfield Row, San Diego, California 92121 (US). **MALIA, Thomas**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **OBMOLOVA, Galina**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **ORT, Tatiana**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **RYCYZYN, Michael**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **SCULLY, Michael**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **SWEET, Raymond**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **TEPLYAKOV, Alexey**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **WHEELER, John**; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). **ALMAGRO, Juan Carlos**; 44 Harvard Ave. #5, Brookline, Massachusetts 02446 (US).

(74) Agents: **JOHNSON, Philip S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

[Continued on next page]

(54) Title: HUMAN ANTI-CD27 ANTIBODIES, METHODS AND USES

Fig. 1



(57) Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

WO 2013/138586 A1

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*